Rocuronium Bromide Injection, Solution
Product Images NDC 51662-1545

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 51662-1545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vial Label (51662 1542 1 Etomidate Injection Vial Label)

This is a warning for a medication called Rocuronium (NDC 55150.226-10) which is a paralyzing agent and can cause respiratory arrest. It is important for facilities to have artificial respiration immediately available. The medication should be stored in a refrigerator between 2 to 8°C (36° to 46°F) and should not be frozen. Once removed from the refrigerator, the medication should be used within 600 days or 30 days if the vial is opened. This medication is distributed by AuroMedics Pharma LLG in E. Windsor, NJ and is made in India. This is a 100 mg per 10 mL multiple dose vial for intravenous use only.*

FDA Label Image

Serialized Label (51662 1545 1 Serialized Label)

FDA Label Image

1 (Clinical P 1)

FDA Label Image

10 (Clinical P 10)

FDA Label Image

2 (Clinical P 2)

FDA Label Image

3 (Clinical P 3)

FDA Label Image

4 (Clinical P 4)

The text is a figure caption describing a graph that shows the relationship between the initial dose of Rocuronium Bromide and the time taken to achieve 80% or greater block by different age groups. The graph has median, 25th and 75th percentile, and individual values for the data. The age groups represented are 18-64 years, and greater than or equal to 65 years, and 10-12 years old. The initial doses of Rocuronium Bromide used in the study were between 0.45 and 1.2 mg/kg.*

FDA Label Image

5 (Clinical P 5)

This is a figure (Figure 2) that compares the duration of clinical effect of Rocuronium Bromide with respect to the initial dose of the drug administered, categorized by age groups. The data shows the median, 25th and 75th percentiles, and individual values. The X-axis represents the initial dose of the drug, while the Y-axis represents the duration of the clinical effect, in minutes. The age groups compared are those over and below 65 years of age as well as children between 3 months and 12 years old.*

FDA Label Image

6 (Clinical P 6)

FDA Label Image

7 (Clinical P 7)

FDA Label Image

8 (Clinical P 8)

FDA Label Image

9 (Clinical P 9)

FDA Label Image

T1 (Clinical T1)

This is a table showing the infusion rates for rocuronium bromide injection based on patient weight and drug delivery rate. The table includes various patient weights and corresponding infusion delivery rates in mL/hr. The rocuronium bromide is provided in a solution containing 0.5mg/mL and 50mg in 100 mL.*

FDA Label Image

T2 (Clinical T2)

This is a table showing the infusion rates for Rocuronium Bromide Injection (1mg/mL) used according to the patient's weight. The table contains columns of patient weight and drug delivery rate (mcg/kg/min) and another table with the infusion delivery rate (mL/hr). The infusion rate varies depending on the weight of the patient. The last row shows that 100mg of Rocuronium Bromide is mixed in 100 mL solution.*

FDA Label Image

T3 (Clinical T3)

This table provides infusion rates using Rocuronium Bromide Injection for patients of different weights to be delivered at certain drug delivery rates. The drug is delivered at a rate of mcg/kg/min, and the infusion delivery rate is represented in mL/hr. The solution contains 500mg Rocuronium Bromide in a 100mL solution.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.